This editorial refers to 'Impact of immature platelets on platelet response to ticagrelor and prasugrel in patients with acute coronary syndrome' † , by I. Bernlochner et al.,
Based on their systemic bioavailability, antiplatelet drugs interact with peripheral platelets as well as with MKs, pro-platelets, and preplatelets in the bone marrow. However, because of the limited accessibility of MKs, RPs provide potential tools for indirectly probing the pharmacological effect of antiplatelet drugs on MK drug targets and the carry-over effect from central MKs to peripheral platelets, and assessing the relevance of the drug target renewal rate. Moreover, due to their higher functional reactivity, RPs might contribute to atherothrombotic complications in certain clinical settings. 1, 2 The hypothesis linking larger platelets to the pathophysiology of acute coronary syndromes (ACS) was first put forward by John Martin and Colleagues in the early 1980s. 3 Almost concomitantly, a role for cyclooxygenase (COX) acetylation in MKs was hypothesized to explain the delayed recovery (2-day lag) of platelet COX-1 after low-dose aspirin withdrawal. 4 Without COX isozyme acetylation in MKs, 10 -12% (and a higher proportion under conditions of accelerated platelet turnover) of newly formed platelets with intact COX-1 activity would appear in the systemic circulation during the 24-h dosing interval of low-dose aspirin administration; while in fact COX-1 activity, as reflected by whole blood thromboxane (TX) B 2 production, is suppressed by 99% throughout the dosing interval. Figure 1 ).
Several studies have described an association between large platelets and/or RPs and coronary heart disease, including ACS, correlating platelet turnover to clinical manifestations of atherothrombosis. 9 -12 However, whether a higher fraction of large platelets is a cause or consequence of ACS (e.g. from platelet consumption on atherosclerotic plaques and consequent accelerated turnover) remains to be determined. Moreover, it is unknown whether the proportion of RPs might decline over time after an acute vascular event, in part due to effective antiplatelet therapy. Interestingly, a reduction in RPs 12 months post-myocardial infarction (MI) has been described recently, 10 consistent with the initial reports of large platelets decreasing after MI. aggregation was correlated to RPs in the prasugrel group but not in the ticagrelor group, in spite of a higher average platelet inhibition associated with prasugrel treatment; and (ii) on maintenance therapy, RPs expressed significantly more P-selectin in response to ADP at the end of the dosing interval (i.e. 1 h before the next intake) as compared with an earlier determination (2 h after the last intake) in the prasugrel group (26.3% vs. 11.9%) but not in the ticagrelor group (13.5% vs. 9.4%). The fact that overall platelet inhibition, as assessed by MEA, was below the threshold for high platelet reactivity in both groups confirms the limitations of arbitrary thresholds of these functional measurements. 5 A correlation between high RPs and reduced prasugrel-induced inhibition of platelet aggregation in patients with ST-segment elevation MI (STEMI) 14 as well as a lack of correlation between RPs and the degree of residual platelet . is associated with a fairly steady inhibition of P-selectin expression on reticulated platelets in acute coronary syndrome (ACS), 13 independently of the platelet renewal rate. A partial recovery of P-selectin expression on ADP-stimulated reticulated platelets (RPs) at 24 h as compared with 2 h has been reported in prasugrel-treated ACS patients 13 (middle panel). A partial recovery of platelet cyclooxygenase-1 (COX-1) activity, as reflected by serum thromboxane (TX) B 2 , has been reported in aspirin-treated patients with essential thrombocythaemia (ET) and type 2 diabetes mellitus (T2DM) 16, 17 (lower panel). The vertical black arrows indicate the timing of drug intake.
Editorial aggregation in non-ST segment elevation (NSTE)-ACS patients on ticagrelor 15 were recently reported and are consistent with the present findings. Study limitations include: (i) lack of parallel measurements of plasma drug levels, when the 'early' and 'late' P-selectin expression on ADP-stimulated RPs were measured; and (ii) lack of repeated measurements to assess the stability of the platelet phenotype over a 12-month treatment period. An inverse correlation between RPs and antiplatelet responsiveness to low-dose aspirin has also been reported in diverse clinical settings such as type 2 diabetes, stable coronary heart disease, ACS, and essential thrombocythaemia. 9,16 -18 Independently of the underlying disorder, a lower platelet inhibition was consistently observed in aspirin-treated patients with the highest RPs. Therefore, the mechanism(s) linking RPs to suboptimal antiplatelet response seems to be independent of the drug class and underlying disease, but rather dependent on the mechanism of drug action (irreversible vs. reversible inhibition), on the half-life of the active drug, and on the kinetics of platelet turnover. An extreme clinical paradigm of this unfavourable combination is exemplified by essential thrombocythaemia, a myeloproliferative neoplasm characterized by persistently enhanced platelet production. In essential thrombocythaemia patients treated with low-dose aspirin, RPs independently predicted poor aspirin responsiveness. 16 A more frequent dosing regimen (100 mg b.i.d.) restored the extent and duration of platelet inhibition, while a higher once-daily dose (200 mg) was not as effective. doubling the once-daily aspirin dose does not increase the duration of its antiplatelet effect, while a b.i.d. regimen prevents the timedependent recovery of COX-1 activity during the dosing interval. Thirdly, the present results provide a rationale for a b.i.d. dosing study of prasugrel in ACS patients with high RPs. Finally, in order to develop a personalized approach to antiplatelet therapy, we clearly need more extensive studies of RPs in different clinical settings, as well as sensitive and reliable mechanism-based biomarkers of antiplatelet drug responsiveness. 6 These data would be essential to inform in silico models in order to simulate the impact of individual pharmacokinetic and pharmacodynamic features of the drug in the face of variable rates of renewal of the drug target.
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